Nordicus Partners Reports $1.5 Million Net Loss for Quarter, No Revenue Generated

Nordicus Partners Corporation has reported its financial results for the three and six months ended September 30, 2025, revealing a net loss of $1.5 million for the quarter and $2.7 million for the half-year period. This marks a significant increase in losses compared to the same periods in 2024, where the company reported losses of $507,396 and $765,565, respectively. The company did not generate any revenue during the current fiscal periods, maintaining the same trend as the previous year. Operating expenses surged to $1.2 million for the quarter and $2.04 million for the six months, driven primarily by increased officer compensation, professional fees, and general administrative costs.

The financial performance reflects a substantial increase in operating expenses, which rose by 137% year-over-year for the quarter and 165% for the half-year. Officer compensation alone increased to $285,398 for the quarter, up from $49,104 in the prior year, largely due to salary increases for key executives and stock-based compensation for newly appointed board members. Professional fees also saw a significant rise, attributed to legal and accounting expenses related to the company's recent acquisitions of Orocidin A/S and Bio-Convert A/S.

In terms of strategic developments, Nordicus has been active in expanding its portfolio through acquisitions. The company completed the acquisition of Orocidin A/S, a preclinical-stage biotechnology firm focused on periodontitis therapies, and Bio-Convert A/S, which is developing treatments for oral leukoplakia. As of September 30, 2025, Nordicus reported total assets of $75.9 million, an increase from $70.2 million at the end of the previous fiscal period, primarily due to the recognition of in-process research and development assets from these acquisitions.

Operationally, Nordicus has not reported any revenue generation, reflecting its ongoing pre-revenue phase. The company’s focus remains on advancing its biotechnology portfolio, which includes three preclinical companies: Orocidin A/S, Bio-Convert A/S, and the newly formed NoviThera ApS, which is developing a monoclonal antibody treatment for psoriasis. The company’s employee headcount has also increased, reflecting its expansion efforts, although specific figures were not disclosed in the filing.

Looking ahead, Nordicus faces challenges related to its liquidity, with cash reserves of $242,155 as of September 30, 2025, which are insufficient to meet operational needs for more than twelve months. The company plans to finance its operations through existing cash and potential private placements of common stock. Management has expressed confidence in its strategic direction, emphasizing the importance of its acquisitions and ongoing research and development efforts to drive future growth and profitability.